Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Uterine Sarcoma: early-phase trial registry
A small indexed set (4 trials) with no open enrollment listed right now.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · none currently recruiting · #4,115 of 28,707 conditions by registered trial count
Recurrent Uterine Sarcoma: 4 US clinical trials tracked, none currently recruiting.
Recurrent Uterine Sarcoma is the subject of 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 2 of these trials.
Enrollment posture brief
Registry condition recurrent-uterine-sarcoma
OPEN 0 | RECR 0% | LATE 0 | EARLY 4 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Recurrent Uterine Sarcoma has no open enrollment in this registry pull (4 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Uterine Sarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Uterine Sarcoma is recruiting below its size-band peers.
0 of 4 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
4 total, page 1 of 1
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
National Cancer Institute (NCI)
NCT00245102
Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies
Case Comprehensive Cancer Center
NCT01079832
Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
National Cancer Institute (NCI)
NCT00378911
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
Wake Forest University Health Sciences
NCT01553539
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Uterine Sarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Uterine Sarcoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Uterine Sarcoma page
4 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Recurrent Uterine Sarcoma trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- National Cancer Institute (NCI) sponsors the most Recurrent Uterine Sarcoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Uterine Sarcoma condition card totals 4 registered trials; most-linked intervention sorafenib tosylate; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.